BioFarma USEF. Expertise in drug discovery projects

Similar documents
Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

In Vitro Pharmacology Services

Experience on HTRF technology in public-private collaborations

Antibody Discovery at Evotec

Propelling GPCR drug discovery through innovative products and services Be the change the market seeks

Drug Targets - an overview of historical success and protein kinase inhibitors - successes and attrition. John P. Overington

Recent years have witnessed an expansion in the disciplines encompassing drug

CHAPTER 4. Milestones of the drug discovery

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Real World Drug Discovery A Chemist's Guide to Biotech and Pharmaceutical Research

Introduction to Assay Development

How Targets Are Chosen. Chris Wayman 12 th April 2012

WHEN MULTIMODE MEETS IMAGING YOU GAIN A WHOLE NEW PERSPECTIVE. EnSight Multimode Plate Reader

Capabilities & Services

Use of a Label-Free Platform in a preclinical Contract Research Organization Environment

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Miniaturized Whole Cell-based GPCR camp Assay Using a Novel Detection System

TARGET VALIDATION. Maaike Everts, PhD (with slides from Dr. Suto)

An Automated, Cell-based Platform for the Rapid Detection of Novel Androgen Receptor Modulators

Impact of Collaborative Robots at The Genomics Institute of the Novartis Research Foundation (GNF) Dan Sipes Novartis Foundation

Quo vadis Drug Discovery

Synergy NEO HTS Multi-Mode Microplate Reader and Life Technologies Reagents

Chemoinformatic Tools for the Hit Discovery Process

BECAUSE CAN T WAIT BREAKTHROUGHS. Drug Discovery Screening Solutions SCREENING SOLUTIONS. Automated Liquid Handling. Assays and Reagents

FRAUNHOFER IME SCREENINGPORT

Specialty Lab Services. Deep science at scale

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Advancing Life Sciences

The Role of Cell Based Imaging in Drug Discovery Dr. Jason Seewoodhary July 2011 Volume 1 Issue 1 Doctors Academy Publications

Targeting the Functional Activity of PrP C as a Novel Strategy for Drug Discovery in Prion Diseases

Program overview. SciLifeLab - a short introduction. Advanced Light Microscopy. Affinity Proteomics. Bioinformatics.

Polypharmacology. Giulio Rastelli Molecular Modelling and Drug Design Lab

Compound Re-Profiling. Dr Robert Scoffin CEO, Cresset

HIGH-THROUGHPUT & PHENOTYPIC SCREENING

Advanced Therapeutic Antibody Discovery with Multiplexed Screening

A Comparison of PerkinElmer s LANCE camp Assay Performance to that of State of the Art Competitive Technologies

leading the way in research & development

Agilent RapidFire 365 High-throughput Mass Spectrometry System ACCELERATING PHARMACEUTICAL DRUG DISCOVERY

SpectraMax Paradigm Microplate Reader

Drug Discovery and Development PHG 311. Prof. Dr. Amani S. Awaad

INTRODUCTORY GUIDE TO CNS DRUG DISCOVERY

Introduction to Drug Design and Discovery

Human ips/es Cell Technology and Its Application to Toxicology Testing

University of Pennsylvania Perelman School of Medicine High Throughput Screening Core

Post-Baccalaureate Program in Pharmaceutical Science. Accelerate your career

TECHNOLOGY PLATFORMS FOR THE STUDY OF ION CHANNEL BIOLOGY AVAILABLE AT REACTION BIOLOGY CORP

BR-10455A. Automated Multiplexed Gene Expression Profiling Process Solutions. Multiplex Quantitative High-throughput

Break the 3D barrier CORNING 3D CELL CULTURE

Biomedical Sciences Graduate Program

The Comprehensive Report

OriGene GFC-Arrays for High-throughput Overexpression Screening of Human Gene Phenotypes

Progress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies

REIMAGINING DRUG DEVELOPMENT:

SHANGHAI MEDICILON INC.

Nuclear Receptor Bio-Assays

Flow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity

a) JOURNAL OF BIOLOGICAL CHEMISTRY b) PNAS c) NATURE

Cellular Assays. A Strategic Market Analysis. Sample Slides

21st Annual International Conference on Drug-Drug Interactions. Zach Mitts Northwest Account Manager

Computational Drug Design

Get started with HTRF

catalogue Key Organics Chemistry Innovation Quality

SureSilencing sirna Array Technology Overview

Ion S5 and Ion S5 XL Systems

Application of Deep Learning to Drug Discovery

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

Ion S5 and Ion S5 XL Systems

Informatics challenges in data management, high-throughput screening and development of predictive models of ADME properties

Sequencing and PCR. Training: Ion S5 and S5 XL Systems workflow training

Z -LYTE fluorescent kinase assay technology. Z -LYTE Kinase Assay Platform

Innovative Solutions for Drug Discovery and Life Sciences Research

Explore the World of End-to-End. Integrated Lab Performance

UAMS ADVANCED DIAGNOSTICS FOR ADVANCING CURE

Trend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital

How to develop effective in vitro assays for early drug discovery

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298

Frumkin, 2e Part 1: Methods and Paradigms. Chapter 6: Genetics and Environmental Health

COMPAS for the Analysis of SELEX Experiments

DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS

PATIENT STRATIFICATION. 15 year A N N I V E R S A R Y. The Life Sciences Knowledge Management Company

System. Dynamic Monitoring of Receptor Tyrosine Kinase Activation in Living Cells. Application Note No. 4 / March

Hitting the target in phenotypic drug discovery: Advances in receptor deconvolution

Pioneering Clinical Omics

Proteomics. Manickam Sugumaran. Department of Biology University of Massachusetts Boston, MA 02125

GENOMICS WORKFLOW SOLUTIONS THAT GO WHERE THE SCIENCE LEADS. Genomics Solutions Portfolio

Applied Protein Services

NANYANG TECHNOLOGICAL UNIVERSITY SEMESTER I EXAMINATION CBC922 Medicinal Chemistry. NOVEMBER TIME ALLOWED: 120 min

Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals

Medicinal Chemistry of Modern Antibiotics

Medicinal Chemistry of Modern Antibiotics

GENOMICS WORKFLOW SOLUTIONS THAT GO WHERE THE SCIENCE LEADS. Genomics Solutions Portfolio

Practical Workshop: Chemical Biology, Drug Discovery and Screening

Expression Profiling for

Web Based Photonic Crystal Biosensors for Drug Discovery & Diagnostics

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

Integrating Molecular Toxicology Earlier in the Drug Development Process

THIS IS WHERE RELIABILITY AND INSPIRATION COME TOGETHER. Multimode Plate Readers

G E N OM I C S S E RV I C ES

The Power to Cure: Therapeutic Innovation in Academia

Transcription:

BioFarma USEF Expertise in drug discovery projects

Since more than 15 years, we have provided custom assay development, compound profiling, high-throughput screening services and collaborations in over 200 drug discovery projects. We can help with any service in your workflow to move your discovery forward from target identification through safety and toxicity testing. The USEF has a state-of-the-art equipment for carrying out assay development projects and screening campaigns with different technological approaches. PHARMACOGENOMICS STUDIES Discovery and analysis of genomic biomarkers for: Patient and disease stratification Response to drugs (efficacy and toxicity) TECHNOLOGICAL APPROACHES: Radioactivity (Filtration and SPA); Absorbance; Fluorescence intensity and polarization; Luminescence; FRET and Homogeneous Time-Resolved Fluorescence; BRET; Alphascreen; Fluorescence Lifetime Imaging; Automated patch-clamp; Label free (Dynamic Mass Redistribution); Automated mobility shift (Lab on a chip); High Content Screening and UPLC/MS/MS. We collaborate with Medicina Xenómica group, which shares with us their genomics technology platforms. Identification of novel therapeutic targets: Genome wide and candidate gene association studies (e.g. Illumina, Affymetrix, Sequenom, Agilent) Next Generation Sequencing (e.g. Ion Torrent, Ion Proton, SOLiD) specific application to pharmacogenomic panels and exome sequencing

TARGET-BASED ASSAYS GPCRs Radioligand binding assays: ADO, NA, DA, 5-HT, M, H 1, LTB 4... CELL-BASED ASSAYS GPCRs Second messenger assays: ADO, NA, DA, 5-HT GPCRs Beta-arrestin translocation assays-bret: GPR35; mu opioid; CX 3 CR1... Phenotypic assays (e.g. cell viability, signaling pathway assays, disease-related assays) Nuclear receptors E.g. AR, ER, PPAR and prostanoids receptors Enzymes Kinases (250 functional assays), phosphodiesterases (15 activity assays); BACE-1 (beta-secretase), acetylcholinesterase; MAO-A, MAO-B; epigenetic enzymes Target deconvolution strategies Ion channels Voltage-gated channels: Ca 2+, K +, herg, Na + Membrane ligand-gated channels: NMDA; 5-HT 3 ; GABAA Biomolecular imaging (FRET microscopy, High-content analysis) Transporters DAT, NAT, 5-HTT

ADMET CUSTOMIZED ASSAYS P450 profiling - induction and inhibition. Targets engagement, permeability (Caco-2); P-glycoprotein substrate; aqueous solubility (ph-dependent). We work to understand your goals and tailor a solution to fit your project guidelines. Our dedicated scientific professionals have access to and expertise in assay solutions across multiple target classes and detection platforms. PRELIMINARY ADMET AND SAFETY ASSAYS We are committed to deliver high-quality data and comprehensive reporting on time, with dedicated project management and proactive communication throughout the project. Safety Specialized cellular assays: cell viability and cell toxicity. In vitro safety panel, including functional pharmacological profiling. We also provide support at every stage of discovery from instrument setup to screening, profiling, and custom services through data analysis. Our team of specialists is comprised of experienced scientists that can help you find answers efficiently and accurately.

The USEF platform provides scientific-technical services for drug discovery: Pharmacogenomics studies to identify biomarkers and novel therapeutic targets Assays development, set up miniaturization and automation Identification of hits, leads and candidates. In vitro preliminary ADMET and safety SERVICES Customized assays development, target engagement, phenotypic and deconvolution assays Chemical libraries (drugs for repurposing, focused libraries, compounds selected in silico over more than 500 clinically relevant targets, epigenetic-targeted compounds) Assessment and execution of complete screening cascades for R&D

BioFarma is an early drug discovery research group linked to the Screening Platform (USEF) at the University of Santiago de Compostela. It has expertise and offers collaboration with public and private institutions in drug discovery projects. BioFarma has a large experience in assaying small molecules and in the fine-tuning and automatization of techniques for implementation in HTS. Find out more at: http://www.usc.es/biofarma/ CIMUS Research Center Avenida de Barcelona S/N Campus Vida, E - 15782 Santiago de Compostela Telephone: (+34) 881 815 459 usef@usc.es Center for Research in Molecular Medicine and Chronic Diseases